Oxra-S 5/100 Mg (Dapagliflozin/Sitagliptin)

Description

Introduction

Oxra-S 5/100 Mg is presented as a tablet containing dapagliflozin 5 mg and sitagliptin 100 mg for type 2 diabetes. The ingredients lower blood glucose through different mechanisms. Whether this combination is appropriate depends on factors including kidney function, other medicines and the person’s diabetes treatment plan.

What Is It?

Dapagliflozin is a sodium–glucose cotransporter 2 (SGLT2) inhibitor. Sitagliptin is a dipeptidyl peptidase 4 (DPP-4) inhibitor. Oxra-S combines the stated strengths in one oral tablet. Product-specific approval details have not been verified; ask a healthcare professional for guidance about its regulatory status and suitability.

How Does It Work?

Dapagliflozin reduces the amount of glucose that the kidneys return to the bloodstream, allowing more glucose to pass into urine. Sitagliptin prolongs the action of incretin hormones. These hormones help increase insulin release when blood glucose is raised and reduce glucose production by the liver.

These actions can lower blood glucose in type 2 diabetes. Their effects do not replace blood glucose monitoring or other parts of a care plan. Kidney function can influence treatment decisions, particularly because dapagliflozin’s glucose-lowering action depends on glucose being filtered by the kidneys.

Common Uses

Oxra-S is presented for type 2 diabetes. Dapagliflozin and sitagliptin are each used to improve blood glucose control in this condition. A healthcare professional can assess whether their combination fits alongside nutrition, physical activity and any other prescribed medicines.

The approved indications for this exact product have not been verified. Claims for other dapagliflozin products, including uses relating to heart failure or kidney disease, should not be assumed to apply to Oxra-S. It is not presented here as a treatment for type 1 diabetes or diabetic ketoacidosis.

Available Strengths

This family is available in 50 mg, 100 mg.

Key Features

• Each stated tablet contains dapagliflozin 5 mg and sitagliptin 100 mg.
• The two ingredients act through different SGLT2 and DPP-4 pathways.
• The product is presented as an oral tablet for type 2 diabetes.
• Its fixed strengths make assessment of kidney function relevant before treatment decisions are made.

Benefits

• Both ingredients have established blood glucose-lowering effects in type 2 diabetes.
• The different mechanisms may provide complementary glucose control when both medicines are clinically appropriate.
• One tablet contains both stated ingredients, although this does not establish that the formulation is appropriate for every treatment plan.

Possible Side Effects

• Dapagliflozin can increase urination and the risk of genital fungal infections and urinary tract infections.
• Fluid loss can contribute to thirst, dizziness, low blood pressure or dehydration.
• Headache can occur with sitagliptin. Other unwanted effects may occur and should be discussed if persistent or troublesome.
• Low blood glucose is more likely when these medicines are used with insulin or medicines that stimulate insulin release.
• Less common but serious concerns include ketoacidosis with dapagliflozin, and pancreatitis or severe allergic reactions with sitagliptin. Severe or persistent symptoms need prompt medical assessment.

Precautions

• Kidney function affects the use of both ingredients. Sitagliptin may need a different strength in people with reduced kidney function, which can affect the suitability of a fixed combination.
• A healthcare professional should know about previous pancreatitis, recurrent urinary or genital infections, dehydration, or a serious reaction to either ingredient.
• Ketoacidosis associated with dapagliflozin can occur even when blood glucose is not markedly raised. Nausea, vomiting, abdominal pain, unusual tiredness or difficult breathing require prompt assessment.
• Pregnancy or breastfeeding calls for a review of diabetes treatment with a healthcare professional.

Additional Precautions

• Illness, reduced food or fluid intake, prolonged fasting and surgery can alter risks associated with SGLT2 inhibitors. A clinician can provide a plan for these circumstances.
• Pain, redness or swelling around the genitals or perineum, particularly with fever or feeling unwell, requires urgent medical attention.
• Symptoms of a severe or persistent urinary infection should be assessed promptly.
• Blood glucose monitoring and follow-up remain important when a diabetes treatment plan changes.

Storage Instructions

• Keep the tablets out of the reach of children and in their original packaging.
• Check the supplied pack for its expiry date and specific storage conditions; these have not been verified for Oxra-S.
• Ask a pharmacist how to dispose of tablets that are expired or no longer needed.

How to Take

• Follow the directions provided by the prescribing healthcare professional and with the supplied medicine.
• Check the ingredients and strength on the pack, especially when other diabetes medicines are also being used.
• Ask a pharmacist or prescriber about timing, missed doses and whether this particular tablet may be split or crushed. Those product-specific instructions have not been verified.
• Do not change a prescribed treatment plan without professional guidance.

Drug Interactions

• Insulin and sulfonylureas, such as gliclazide, can increase the risk of low blood glucose when used with glucose-lowering medicines.
• Diuretics may increase the risk of fluid loss or low blood pressure associated with dapagliflozin.
• Sitagliptin may require additional consideration when used with digoxin.
• A clinician or pharmacist should review all prescribed medicines, over-the-counter products and supplements for possible interactions.

Why Choose This Product?

• It contains the stated 5 mg dapagliflozin and 100 mg sitagliptin strengths in a single tablet.
• Its ingredients target blood glucose through kidney glucose excretion and incretin activity.
• Its defined combination allows a clinician to assess whether both ingredients and strengths fit an individual treatment plan.

Frequently Asked Questions (FAQs)

What ingredients does Oxra-S contain?

The stated ingredients are dapagliflozin 5 mg and sitagliptin 100 mg per tablet.

What condition is it presented for?

It is presented for type 2 diabetes. Its product-specific approved indications have not been verified.

Do the ingredients work in the same way?

No. Dapagliflozin increases glucose excretion in urine; sitagliptin acts through incretin hormones.

Can low blood glucose occur?

The risk is greater when glucose-lowering treatment is combined with insulin or a sulfonylurea.

Why is kidney function relevant?

Kidney function affects treatment decisions for both ingredients and may affect whether this fixed combination is suitable.

Can urinary or genital infections occur?

Yes. Dapagliflozin can increase these risks. New or persistent symptoms warrant medical assessment.

Which symptoms need urgent attention?

Persistent severe abdominal pain, difficult breathing, or genital or perineal pain and swelling with fever need urgent assessment.

Can it be used during pregnancy or breastfeeding?

Ask a healthcare professional for product-specific guidance. Treatment may need reassessment.

What if a tablet is missed?

Check the instructions supplied with the medicine or ask a pharmacist. Avoid taking an extra dose without guidance.

Related Products

• Oxra-S 5/50 Mg (Dapagliflozin/Sitagliptin)
• Oxra-S 5/100 Mg (Dapagliflozin/Sitagliptin)
• Glimepiride 1 mg Australia
• Miglitol 50 mg Australia
• Acarbose 25 mg Australia
• Bromocriptine 2.5 mg Australia